A single-centerc phase I, dose-escalation trial evaluating 4 escalating dosing schedules of single injected EBViNT for Epstein-Barr Virus (EBV)-positive Tumors.
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2017
At a glance
- Drugs Epstein-Barr-virus-induced-adoptive-T-Cell-Therapy-Eutilex (Primary)
- Indications Epstein-Barr virus infections; Solid tumours
- Focus Adverse reactions
- 19 Jan 2017 New trial record
- 21 Mar 2016 Results published in the Journal of Immunotherapy 2016.